Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
Phase II Study of Adjuvant Cisplatin and Docetaxel in Non-small Cell Lung Cancer
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
Phase II Study of Adjuvant Cisplatin and Docetaxel in Non-small Cell Lung Cancer
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase I Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase I Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC
Status: Enrolling
Updated:  10/1/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC
Status: Enrolling
Updated: 10/1/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/1/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/1/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Aging and Cancer Effects (ACE) Study
Aging and Cancer: The Effects of Comorbidities on Cancer and it's Treatment
Status: Enrolling
Updated:  10/1/2015
University of Wisconsin
mi
from
Madison, WI
Aging and Cancer Effects (ACE) Study
Aging and Cancer: The Effects of Comorbidities on Cancer and it's Treatment
Status: Enrolling
Updated: 10/1/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease
Optical Coherence Tomography of Human Airways
Status: Enrolling
Updated:  10/1/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease
Optical Coherence Tomography of Human Airways
Status: Enrolling
Updated: 10/1/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
A Pilot Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
Status: Enrolling
Updated:  10/5/2015
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
A Pilot Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
Status: Enrolling
Updated: 10/5/2015
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Cleveland Clinic Florida
mi
from
Weston, FL
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Jacobi Medical Center
mi
from
Bronx, NY
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Cleveland Clinic
mi
from
Cleveland, OH
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Abramson Cancer Center
mi
from
Philadelphia, PA
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
UT Southwestern
mi
from
Dallas, TX
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Peninsula Oncology Centre
mi
from
Frankston,
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Peninsula Oncology Centre
mi
from
Frankston,
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Moores Cancer Center University of California, San Diego, Site #099
mi
from
La Jolla, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Moores Cancer Center University of California, San Diego, Site #099
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Kaiser Permanente
mi
from
San Diego, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Kaiser Permanente
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Yale Cancer Center
mi
from
New Haven, CT
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Cancer Center of South Florida
mi
from
Lake Worth, FL
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Cancer Center of South Florida
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
University of Chicago
mi
from
Chicago, IL
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
UNC Health Care; N.C. Cancer Hospital Infusion/Inpatient Pharmacy (CHIP)
mi
from
Chapel Hill, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
UNC Health Care; N.C. Cancer Hospital Infusion/Inpatient Pharmacy (CHIP)
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Levine Cancer Institute-Concord/Clinical Trials (Site 056)
mi
from
Charlotte, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Levine Cancer Institute-Concord/Clinical Trials (Site 056)
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (Site 013)
mi
from
Philadelphia, PA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (Site 013)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Swedish Cancer Institute
mi
from
Seattle, WA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
City of Hope
mi
from
Duarte, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
St Vincent's Hospital Melbourne (Site997)
mi
from
Fitzroy,
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
St Vincent's Hospital Melbourne (Site997)
mi
from
Fitzroy,
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
University of California, San Diego
mi
from
San Diego, CA
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated:  10/6/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated: 10/6/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated:  10/6/2015
University of California, Irvine Medical Center Pharmacy
mi
from
Orange, CA
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated: 10/6/2015
University of California, Irvine Medical Center Pharmacy
mi
from
Orange, CA
Click here to add this to my saved trials
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated:  10/6/2015
University of California, Irving - Medical Center
mi
from
Orange, CA
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated: 10/6/2015
University of California, Irving - Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated:  10/6/2015
University of California Irvin
mi
from
Orange, CA
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Status: Enrolling
Updated: 10/6/2015
University of California Irvin
mi
from
Orange, CA
Click here to add this to my saved trials